Bayesian Capital Management, LP Adaptimmune Therapeutics PLC Transaction History

Bayesian Capital Management, LP

  • $788 Million
  • Q4 2024

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2023

Nov 14, 2023
SELL
$0.73 - $1.04 $803 - $1,144
-1,100 Reduced 9.49%
10,486 $8,000
Q2 2023

Aug 14, 2023
SELL
$0.9 - $1.51 $2,880 - $4,832
-3,200 Reduced 21.64%
11,586 $10,000
Q1 2023

May 15, 2023
BUY
$1.06 - $2.16 $15,673 - $31,937
14,786 New
14,786 $16,000

Others Institutions Holding ADAP

# of Institutions
83
Shares Held
123M
Call Options Held
34.2K
Put Options Held
16.3K
View Full List

About Adaptimmune Therapeutics PLC

ADAP Quotes by TradingView
  • Ticker ADAP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 163,370,000
  • Market Cap $73.5M
  • Description
  • Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4...
More about ADAP
Track This Portfolio

Track Bayesian Capital Management, LP Portfolio

Follow Bayesian Capital Management, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bayesian Capital Management, LP, based on Form 13F filings with the SEC.

News

Stay updated on Bayesian Capital Management, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email